Literature DB >> 25384064

Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base.

John L Mikell1, Theresa W Gillespie, William A Hall, Dana C Nickleach, Yuan Liu, Joseph Lipscomb, Suresh S Ramalingam, Raj S Rajpara, Seth D Force, Felix G Fernandez, Taofeek K Owonikoko, Rathi N Pillai, Fadlo R Khuri, Walter J Curran, Kristin A Higgins.   

Abstract

INTRODUCTION: Use of postoperative radiotherapy (PORT) in non-small-cell lung cancer remains controversial. Limited data indicate that PORT may benefit patients with involved N2 nodes. This study evaluates this hypothesis in a large retrospective cohort treated with chemotherapy and contemporary radiation techniques.
METHODS: The National Cancer Data Base was queried for patients diagnosed 2004-2006 with resected non-small-cell lung cancer and pathologically involved N2 (pN2) nodes also treated with chemotherapy. Multivariable Cox proportional hazards model was used to assess factors associated with overall survival (OS). Inverse probability of treatment weighting (IPTW) using the propensity score was used to reduce selection bias. OS was compared between patients treated with versus without PORT using the adjusted Kaplan-Meier estimator and weighted log-rank test based on IPTW.
RESULTS: Two thousand and one hundred and fifteen patients were eligible for analysis. 918 (43.4%) received PORT, 1197 (56.6%) did not. PORT was associated with better OS (median survival time 42 months with PORT versus 38 months without, p = 0.048). This effect was significant in multivariable and IPTW Cox models (hazard ratio: 0.87, 95% confidence interval: 0.78-0.98, p = 0.026, and hazard ratio: 0.89, 95% confidence interval: 0.79-1.00, p = 0.046, respectively). No interaction was seen between the effects of PORT and number of involved lymph nodes (p = 0.615).
CONCLUSIONS: PORT was associated with better survival for patients with pN2 nodes also treated with chemotherapy. No interaction was seen between benefit of PORT and number of involved nodes. These findings reinforce the benefit of PORT for N2 disease in modern practice using the largest, most recent cohort of chemotherapy-treated pN2 patients to date.

Entities:  

Mesh:

Year:  2015        PMID: 25384064      PMCID: PMC4336617          DOI: 10.1097/JTO.0000000000000411

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  46 in total

1.  Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.

Authors:  Damien Urban; Jair Bar; Benjamin Solomon; David Ball
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

2.  Need for new powered trials to assess the role of post-operative radiotherapy for stage III non-small cell lung cancer.

Authors:  Cécile Le Pechoux; Rodrigo Arriagada; Jean-Pierre Pignon
Journal:  Radiother Oncol       Date:  2014-07-15       Impact factor: 6.280

3.  Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer.

Authors:  R Bütof; K Kirchner; S Appold; S Löck; A Rolle; G Höffken; M Krause; M Baumann
Journal:  Strahlenther Onkol       Date:  2014-01-12       Impact factor: 3.621

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

Authors:  Rodrigo Arriagada; Bengt Bergman; Ariane Dunant; Thierry Le Chevalier; Jean-Pierre Pignon; Johan Vansteenkiste
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

6.  A new irradiation system for lung cancer combining linear accelerator, computed tomography, patient self-breath-holding, and patient-directed beam-control without respiratory monitoring devices.

Authors:  Hiroshi Onishi; Kengo Kuriyama; Takafumi Komiyama; Shiho Tanaka; Naoki Sano; Yoshihito Aikawa; Yoshihito Tateda; Tsutomu Araki; Satoshi Ikenaga; Minoru Uematsu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

Review 7.  Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis.

Authors:  Charlotte Billiet; Herbert Decaluwé; Stephanie Peeters; Johan Vansteenkiste; Christophe Dooms; Karin Haustermans; Paul De Leyn; Dirk De Ruysscher
Journal:  Radiother Oncol       Date:  2013-10-04       Impact factor: 6.280

8.  Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.

Authors:  Anurag K Singh; Mary Ann Lockett; Jeffrey D Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-02-01       Impact factor: 7.038

9.  Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial.

Authors:  Wen-yi Shen; Jian Ji; Yang-song Zuo; Juan Pu; Yan-mei Xu; Cheng-dong Zong; Guang-zhou Tao; Xiao-fei Chen; Fu-zhi Ji; Xi-lei Zhou; Ji-hua Han; Cheng-shi Wang; Jiang-guo Yi; Xi-long Su; Wei-guo Zhu
Journal:  Radiother Oncol       Date:  2013-10-31       Impact factor: 6.280

10.  Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.

Authors:  Inga S Grills; Di Yan; Alvaro A Martinez; Frank A Vicini; John W Wong; Larry L Kestin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-11-01       Impact factor: 7.038

View more
  36 in total

1.  The more and the heavier may not always be an answer.

Authors:  Hongryull Pyo; Se-Hoon Lee; Jhingook Kim
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Postoperative Radiotherapy for Resected Stage IIIA-N2 Non-small-cell Lung Cancer: A Population-Based Time-Trend Study.

Authors:  Wan-Qin Zeng; Wen Feng; Li Xie; Chen-Chen Zhang; Wen Yu; Xu-Wei Cai; Xiao-Long Fu
Journal:  Lung       Date:  2019-11-08       Impact factor: 2.584

3.  Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer.

Authors:  Ugur Selek; Joe Y Chang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

4.  Management of small-cell lung cancer with radiotherapy-a pan-Canadian survey of radiation oncologists.

Authors:  J Shahi; J R Wright; Z Gabos; A Swaminath
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

5.  Optimal sequencing of adjuvant chemotherapy and radiation therapy in resected non-small cell lung cancer with pathological N2 disease.

Authors:  George Rodrigues
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

6.  CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.

Authors:  Q Wang; J Ma; Y Lu; S Zhang; J Huang; J Chen; J-X Bei; K Yang; G Wu; K Huang; J Chen; S Xu
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

7.  Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.

Authors:  Jamie E Chaft; Mark Dunphy; Jarushka Naidoo; William D Travis; Matthew Hellmann; Kaitlin Woo; Robert Downey; Valerie Rusch; Michelle S Ginsberg; Christopher G Azzoli; Mark G Kris
Journal:  J Thorac Oncol       Date:  2015-12-25       Impact factor: 15.609

8.  Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.

Authors:  Whitney S Brandt; Wanpu Yan; Jonathan E Leeman; Kay See Tan; Bernard J Park; Prasad S Adusumilli; Matthew J Bott; Daniela Molena; James Isbell; Jamie Chaft; Andreas Rimner; David R Jones
Journal:  Ann Thorac Surg       Date:  2018-05-26       Impact factor: 4.330

Review 9.  Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  A Gómez; J A González; F Couñago; C Vallejo; F Casas; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2015-08-18       Impact factor: 3.405

10.  Sequencing postoperative radiotherapy and adjuvant chemotherapy in non-small cell lung cancer: unanswered questions on the not evidence-based approach.

Authors:  Lucyna Kepka; Joanna Socha; Monika Rucinska; Ewa Wasilewska-Tesluk; Katarzyna Komosinska
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.